Tectonic Therapeutic (NASDAQ:TECX) Shares Down 8.4% – What’s Next?

Tectonic Therapeutic, Inc. (NASDAQ:TECX)’s share price traded down 8.4% on Monday . The company traded as low as $33.26 and last traded at $32.6380. Approximately 74,839 shares were traded during mid-day trading, a decline of 72% from the average session volume of 264,711 shares. The stock had previously closed at $35.62.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tectonic Therapeutic in a research note on Friday, July 17th. Wells Fargo & Company decreased their price objective on Tectonic Therapeutic from $101.00 to $93.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Zacks Research upgraded Tectonic Therapeutic from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 18th. Raymond James Financial raised Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $76.00 to $81.00 in a research note on Tuesday, May 26th. Finally, Wall Street Zen upgraded Tectonic Therapeutic from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.80.

Tectonic Therapeutic Stock Down 13.0%

The company has a market capitalization of $606.05 million, a P/E ratio of -6.78 and a beta of 3.28. The firm has a fifty day simple moving average of $33.16 and a 200-day simple moving average of $30.08.

Tectonic Therapeutic (NASDAQ:TECX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($1.18) earnings per share for the quarter, beating the consensus estimate of ($1.35) by $0.17. On average, sell-side analysts predict that Tectonic Therapeutic, Inc. will post -5.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tectonic Therapeutic

A number of hedge funds and other institutional investors have recently made changes to their positions in TECX. Braidwell LP lifted its position in Tectonic Therapeutic by 25.9% in the 4th quarter. Braidwell LP now owns 927,524 shares of the company’s stock valued at $19,348,000 after acquiring an additional 190,657 shares in the last quarter. Baker BROS. Advisors LP boosted its stake in shares of Tectonic Therapeutic by 803.4% during the 4th quarter. Baker BROS. Advisors LP now owns 903,400 shares of the company’s stock worth $18,845,000 after acquiring an additional 803,400 shares during the period. BlackRock Inc. acquired a new stake in Tectonic Therapeutic in the 2nd quarter worth about $29,652,000. First Light Asset Management LLC acquired a new stake in Tectonic Therapeutic in the 1st quarter worth about $20,022,000. Finally, 5AM Venture Management LLC boosted its holdings in Tectonic Therapeutic by 18.6% in the 4th quarter. 5AM Venture Management LLC now owns 606,660 shares of the company’s stock valued at $12,655,000 after purchasing an additional 95,000 shares during the period. 62.63% of the stock is currently owned by institutional investors and hedge funds.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.